The present disclosure provides compounds, pharmaceutical compositions, and methods for modulating one or more transcription factors such as AHR or NRF2

Compounds targeting NRF2 and AHR transcription factors address gene expression disruptions, effectively managing associated diseases by modulating cytokine production and cellular processes.

WO2026236698A1PCT designated stage Publication Date: 2026-11-12MARVELBIOME INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027426
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Mutations in transcription factor genes lead to altered gene expression, disrupting normal cellular processes and contributing to diseases such as cancers, autoimmune disorders, and developmental defects.

Method used

Development of compounds that regulate the activity of transcription factors NRF2 and AHR by activating or inhibiting their expression, thereby modulating cytokine production and cellular processes.

Benefits of technology

The compounds effectively manage diseases associated with NRF2 and AHR, including inflammatory diseases, cancers, metabolic disorders, and neurodegenerative disorders, by regulating cytokine expression and cellular functions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027426_12112026_PF_FP_ABST
    Figure US2026027426_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides compounds, pharmaceutical compositions, and methods for modulating one or more transcription factors such as AHR or NRF2.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No. 2013404-0236COMPOUNDS AND METHODS FOR MODULATING ACTIVITY OF TRANSCRIPTION FACTORSCROSS REFERENCE TO RELATED APPLICATIONS

[0001] The present application claims priority to United States Provisional Patent Application No. 63 / 803,175 filed May 9, 2025, the entire contents of which are hereby incorporated by reference in their entirety.BACKGROUND

[0002] Transcription factors are proteins that regulate gene expression, and when they are misregulated or mutated, they can contribute to various diseases, including cancers, autoimmune disorders, and developmental defects. Mutations in transcription factor genes can lead to altered gene expression, potentially disrupting normal cellular processes and leading to disease development.SUMMARY

[0003] In some embodiments, the present disclosure provides compounds and methods of regulating cellular processes such as cytokine production and expression of transcription factors nuclear factor erythroid 2-related factor (NRF2) and aryl hydrocarbon receptor (AHR). In some embodiments, a compound provided herein induces expression levels of one or more cytokines. In some embodiments, a compound provided herein reduces expression levels of one or more cytokines. In some embodiments, a compound provided herein activates one or more transcription factors such as nuclear factor erythroid 2-related factor (NRF2) and aryl hydrocarbon receptor (AHR). In some embodiments, a compound provided herein activates nuclear factor erythroid 2-related factor (NRF2) and aryl hydrocarbon receptor (AHR). In some embodiments, a compound provided herein activates one of nuclear factor erythroid 2-related factor (NRF2) and aryl hydrocarbon receptor (AHR). In some embodiments, a compound provided herein activates nuclear factor erythroid 2-related factor (NRF2) but does not activate aryl hydrocarbon receptor (AHR). In some embodiments, a compound provided herein activates aryl hydrocarbon receptor (AHR) but does not activate nuclear factor erythroid 2-related factor (NRF2).1 Of 3813506481v1Attorney Docket No. 2013404-0236

[0004] In some embodiments, the present disclosure provides a method of activating NRF2, the method comprising contacting a biological sample or administering to a patient a compound of formula IA:IAor a pharmaceutically acceptable salt thereof, wherein:X is -CH2-;R1is Ci-6 aliphatic, -(CH2)xCy’, or -(CH2)yN(R)2;R2is Ci-6 aliphatic or Cy2;Cy1is phenyl or a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Cy2is a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur or a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R3and R3are each independently hydrogen or -CH3;R is hydrogen or C1-6 aliphatic;x is 0-3; andy is 2-4.

[0005] In some embodiments, a method of activating NRF2 comprises contacting a biological sample or administering to a patient a compound of formula IA, wherein R2is Cy2. In some such embodiments, Cy2is a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, a method of activating NRF2 comprises contacting a biological sample or administering to a patient a compound of formula IA, wherein R2is C1-6 aliphatic.

[0006] In some embodiments, the present disclosure provides a method of activating AHR, the method comprising contacting a biological sample or administering to a patient a compound of formula IB:2 of 3813506481v1Attorney Docket No. 2013404-0236or a pharmaceutically acceptable salt thereof, wherein:X is -O-;R1is Ci-6 aliphatic,R2is Ci-6 aliphaticCy1is phenyl or a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Cy2is phenyl, a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;R3and R3are each independently hydrogen or -CH3;R is hydrogen or C1-6 aliphatic;x is 0-3; andy is 2-4.

[0007] In some embodiments, a method of activating AHR comprises contacting a biological sample or administering to a patient a compound of formula IB, wherein at least one of Cy1and Cy2is phenyl.

[0008] In some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of any one of formulas I, IA, IB, I-a, I-a-z, I-a-zz, I-a-zzz, I-a-zv, I-a-v, I-a-vz, I-b, I-b-z, I-b-zz, or I-b-zzz, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0009] In some embodiments, the present disclosure provides a use of a compound of any one of formulas I, IA, IB, I-a, I-a-z, I-a-zz, I-a-zzz, I-a-zv, I-a-v, I-a-vz, I-b, I-b-z, I-b-zz, or I-b-zzz, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use in treating a disease or disorder associated with or modulated by AHR or NRF2.3 of 3813506481v1Attorney Docket No. 2013404-0236

[0010] In some embodiments, the present disclosure provides a compound for use in medicine. In some embodiments, a compound for use in medicine is a compound of any one of formulas I, IA, IB, I-a, I-a-z, I-a-zz, I-a-zzz, I-a-zv, I-a-v, I-a-vz, I-b, I-b-z, I-b-zz, or I-b-zzz, or a pharmaceutically acceptable salt thereof.

[0011] In some embodiments, the present disclosure provides a compound for use in a method of treating a disease or disorder associated with or modulated by AHR or NRF2, the method comprising administering to a patient a compound of any one of formulas 1, 1A, IB, 1-a, I-a-z, I-a-zz, I-a-zzz, I-a-zv, I-a-v, I-a-vz, I-b, I-b-z, I-b-zz, or I-b-zzz, or a pharmaceutically acceptable salt thereof.

[0012] In some embodiments, the present disclosure provides a compound for use in treating a disease or disorder associated with or modulated by AHR or NRF2. In some embodiments, a compound for use in treating a disease or disorder associated with or modulated by AHR or NRF2 is a compound of any one of formulas I, IA, IB, I-a, I-a-z, I-a-zz, I-a-zzz, I-a-zv, I-a-v, I-a-vz, I-b, I-b-z, I-b-zz, or I-b-zzz, or a pharmaceutically acceptable salt thereof.

[0013] In some embodiments, the present disclosure provides a method of treating a disease or disorder associated with or modulated by AHR or NRF2, the method comprising administering to a patient a compound of any one formulas I, IA, IB, I-a, I-a-z, I-a-zz, I-a-zzz, I-a-zv, I-a-v, I-a-vz, I-b, I-b-z, I-b-zz, or I-b-zzz, or a pharmaceutically acceptable salt thereof.

[0014] In some embodiments, a disease or disorder associated with or modulated by AHR or NRF2 is selected from an inflammatory disease or disorder, a cancer, a metabolic disorder such as diabetes, an age-related disorder, fibrosis, a disorder of the central nervous system, or a neurodegenerative disorder. In some embodiments, a neurodegenerative disorder is a dementia-type disease such as Alzheimer’s disease, frontotemporal dementia, chronic traumatic encephalopathy (CTE), Lewy body dementia, limbic predominant age-related TDP-43 encephalopathy (LATE), a demyelinating disease such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), a Parkinsonism-type disease such as Parkinson’s disease and other forms of parkinsonism, a motor neuron disease such as amyotrophic lateral sclerosis (ALS) and progressive supranuclear palsy (PSP), or a prion disease such as Creutzfeldt-Jakob disease, or Huntington’s disease. In some embodiments, an inflammatory disease or disorder is an inflammatory skin disorder.4 of 3813506481v1Attorney Docket No. 2013404-0236

[0015] In some embodiments, the present disclosure provides a method of modulating a transcription factor, e.g., AHR orNRF2, the method comprising contacting a biological sample or administering to a patient a compound of any one formulas I, IA, IB, I-a, I-a-z, I-a-zz, I-a-zzz, I-a-zv, I-a-v, I-a-vz, I-b, I-b-z, I-b-zz, or I-b-zzz, or a pharmaceutically acceptable salt thereof.

[0016] In some embodiments, the present disclosure provides a method of regulating one or more of cell quiescence, cell differentiation, or cell migration, the method comprising contacting a biological sample or administering to a patient a compound of any one formulas 1, IA, IB, I-a, I-a-z, I-a-zz, I-a-zzz, I-a-zv, I-a-v, I-a-vz, I-b, I-b-z, I-b-zz, or I-b-zzz, or a pharmaceutically acceptable salt thereof

[0017] In some embodiments, the present disclosure provides a method of regulating the expression levels of one or more cytokines, the method comprising contacting a biological sample or administering to a patient a compound of any one formulas I, IA, IB, I-a, I-a-z, I-a-zz, I-a-zzz, I-a-zv, I-a-v, I-a-vz, I-b, I-b-z, I-b-zz, or I-b-zzz, or a pharmaceutically acceptable salt thereof. In some embodiments, a cytokine whose expression levels can be regulated by a compound of any one formulas I, IA, IB, I-a, I-a-z, I-a-zz, I-a-zzz, I-a-zv, I-a-v, I-a-vz, I-b, I-b-z, I-b-zz, or I-b-zzz, or a pharmaceutically acceptable salt thereof, is selected from eotaxin, IL-7, MIG, IL-la, IL-2, G-CSF, IL-16, 6Ckine / Exodus2, GM-CSF, IL-10, IL-15, IL-3, IL-4, IL-6, IL-11, IL-17, LIF, LIX, M-CSF, MDC, IL-13, MCP-1, MCP-5, MIP-la, MIP-10, IFN0-1, TNFa, and VEGF.

[0018] In some embodiments, a compound of any one formulas I, IA, IB, I-a, I-a-z, I-a-zz, I-a-zzz, I-a-zv, I-a-v, I-a-vz, I-b, I-b-z, I-b-zz, or I-b-zzz, or a pharmaceutically acceptable salt thereof, reduces the expression level of at least one cytokine selected from G-CSF, IL- 16, 6Ckine / Exodus2, GM-CSF, IL- 10, IL-3, IL-4, IL-6, IL- 11, IL- 17, LIF, LIX, M-CSF, MCP-1, MCP-5, MIP-la, MIP-10, IFN0-1, TNFa, and VEGF as compared to a baseline level.

[0019] In some embodiments, a compound of any one formulas I, IA, IB, I-a, I-a-z, I-a-zz, I-a-zzz, I-a-zv, I-a-v, I-a-vz, I-b, I-b-z, I-b-zz, or I-b-zzz, or a pharmaceutically acceptable salt thereof, increases or induces the expression level of at least one cytokine selected from eotaxin, IL-7, MIG, IL-la, IL-2, IL-15, MDC, and IL-13 as compared to a baseline level.5 of 3813506481v1Attorney Docket No. 2013404-0236BRIEF DESCRIPTION OF THE DRAWING

[0020] FIG. 1 is a line graph that depicts the reduction in ear thickness in mice treated with compound 1-4 in an oxazolone-induced atopic dermatitis model.

[0021] FIG. 2 is a bar graph that depicts the reduction in epithelial thickness in mice treated with compound 1-4 in an oxazolone-induced atopic dermatitis model.

[0022] FIG. 3A, FIG. 3B, and FIG. 3C are bar graphs that depict the changes in cytokines induced or repressed in mice treated topically with compound 1-4 in an oxazolone-induced atopic dermatitis model.

[0023] FIG. 4 is a plot depicting the concentration of compound 1-4 in brain tissue of mice treated with compound 1-4 i.p. as compared to vehicle.

[0024] FIG. 5 is a plot depicting the concentration of compound 1-4 in brain tissue of mice treated with compound 1-4 p.o. as compared to vehicle.DETAILED DESCRIPTION1. Definitions

[0025] Compounds provided herein include those described generally above, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this disclosure, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March’s Advanced Organic Chemistry”, 5thEd., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.

[0026] The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other6 of 3813506481v1Attorney Docket No. 2013404-0236embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups.

[0027] The terms “heteroaryl” and “heteroar-”, used alone or as part of a larger moiety, e.g., “heteroaralkyl”, or “heteroaralkoxy”, refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 147t electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms “heteroaryl” and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring.Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4 / / quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, and phenoxazinyl. A heteroaryl group may be mono- or bicyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring”, “heteroaryl group”, or “heteroaromatic”, any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.

[0028] As used herein, the terms “heterocycle”, “heterocyclyl”, “heterocyclic radical”, and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term “nitrogen” includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2 7-pyrrolyl), NH (as in pyrrolidinyl), or+NR (as in N- -substituted pyrrolidinyl).7 of 3813506481v1Attorney Docket No. 2013404-0236

[0029] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms “heterocycle”, “heterocyclyl”, “heterocyclyl ring”, “heterocyclic group”, “heterocyclic moiety”, and “heterocyclic radical”, are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the heterocyclyl ring. A heterocyclyl group may be mono- or bicyclic. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.

[0030] As described herein, compounds provided herein may contain “optionally substituted” moieties. In general, the term “substituted”, whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.Combinations of substituents envisioned by this dislcosure are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable”, as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

[0031] Suitable monovalent substituents on a substitutable carbon atom of an “optionally substituted” group are independently halogen; -(CH 2)0 4R0; -(CH2)o 4OR0; -0(CH2)o-4R°, -O-(CH2)O4C(O)ORO; -(CH2)O4CH(ORO)2; -(CH2)O-4SR°; -(CH2)0-4Ph, which may be substituted with R°; -(CH2)o-40(CH2)o iPh which may be substituted with R°; -CH=CHPh, which may be substituted with R°; -(CH2)o40(CH2)o 1 -pyridyl which may be substituted with R°; -NO2; -CN; -N3; -(CH2)O-4N(R°)2; -(CH2)O-4N(R°)C(0)R°; -N(R°)C(S)R°; -(CH2)O- 8 of 3813506481v1Attorney Docket No. 2013404-02364N(R°)C(O)NR°2; -N(RO)C(S)NR°2; -(CH2)O 4N(RO)C(O)OR°; -N(R°)N(R°)C(O)R°; -N(R°)N(R°)C(O)NR°2; -N(R°)N(R°)C(O)OR°; -(CH2O4C(0 RO; -C(S)R°; -(CH2)0 4C(O)ORC; -(CH2)O 4C(O)SRO; -(CH2 4 4C(O OSiR°3; -(CH2)o4OC(O)R°; -OC(0)(CH2)o4SRO, SC(S)SR°; -(CH2 O 4SC(0)RO; -(CH2)O 4C(O)NR°2; -C(S)NRO2; -C(S)SR°; -SC(S)SR°, -(CH2)O4OC(O)NRO2; -C(O)N(OR°)R°; -C(O)C(O)R°; -C(O)CH2C(O)RO; -C(NOR°)R°; -(CH2)O SSR°; -(CH2)4S(02RO; -(CH2)O-4S(O)2OR°; -(CH2)O 4OS(O)2RO; -S(O)2NR°2; -(CH2)O 4S(O)RO; -N(RO)S(O)2NR°2; -N(RO)S(O)2R°; -N(OR°)R°; -C(NH)NRO2; -P(O)2R°; -P(0)RO2; -OP(O)RO2; -0P(0)(0RO)2; SiR°3; — (Ci-4 straight or branched alkylene)O-N(R°)2; or - (C w straight or branched alkylene)C(O)O-N(R°)2, wherein each R° may be substituted as defined below and is independently hydrogen, Ci-6 aliphatic, -CH2Ph, -0(CH2)o iPh, -CH2-(5-6 membered heteroaryl ring), or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.

[0032] Suitable monovalent substituents on R° (or the ring formed by taking two independent occurrences of R° together with their intervening atoms), are independently halogen, -(CH2)o2R*, -(haloR’), -(CH2)o2OH, -(CH2)o2OR’, -(CH2)02CH(OR*)2; -O(haloR’), -CN, -N3, -(CH2)o-2C(0)R*, -(CH2)o2C(O)OH, -(CH2)o2C(O)OR*, -(CH2)O2SR*, -(CH2)O2SH, -(CH2)O-2NH2, -(CH2)O2NHRe, -(CH2)O2NR*2, -NO2, -SiR*3, -OSiR*3, -C(O)SR" - (Ci^i straight or branched alkylene)C(O)OR", or-SSR* wherein each R" is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently selected from Ci-4aliphatic, -CH2Ph, 0(CH2)o iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =0 and =S.

[0033] Suitable divalent substituents on a saturated carbon atom of an “optionally substituted” group include the following: =0, =S, =NNR*2, =NNHC(O)R*, =NNHC(O)OR*, =NNHS(O)2R*, =NR*,wherein each independent 9 of 3813506481v1Attorney Docket No. 2013404-0236occurrence of R* is selected from hydrogen, Ci-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an “optionally substituted” group include: -O(CR*2)2 3O-, wherein each independent occurrence of R* is selected from hydrogen, Ci-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0034] Suitable substituents on the aliphatic group of R* include halogen, - R*, -(haloR*), -OH, -OR*, O(haloR*), -CN, C(O)OH, C(O)OR*, -NH2, -NHR*, NR*2, or -NO2, wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C1-4 aliphatic, -CH2Ph, -0(CH2)o iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0035] Suitable substituents on a substitutable nitrogen of an “optionally substituted” group include -R', -NR'2, -C(O)Rf, -C(O)ORf, -C(O)C(O)Rf, -C(O)CH2C(O)R, -S(O)2R+, -S(O)2NRf2, -C(S)NR 2, -C(NH)NR 2, or-N(R^)S(O)2Rt; wherein each R' is independently hydrogen, C1-6 aliphatic which may be substituted as defined below, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R', taken together with their intervening atom(s) form an unsubstituted 3-12-membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0036] Suitable substituents on the aliphatic group of R' are independently halogen, -R*, -(haloR*), -OH, -OR*, -O(haloR*), -CN, -C(O)OH, -C(O)OR*, -NH2, -NHR*, -NR*2, or -NO2, wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C1-4 aliphatic, -CH2PI1, -0(CH2)o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0037] As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the 10 of 3813506481v1Attorney Docket No. 2013404-0236tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds provided herein include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.

[0038] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N (C i 4al ky 1 )4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.

[0039] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the disclosure. Unless otherwise stated, all tautomeric forms 11 of 3813506481v1Attorney Docket No. 2013404-0236of the compounds provided herein are within the scope of the disclosure. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a13C- or14C-enriched carbon are within the scope of this disclosure. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present disclosure.

[0040] “Therapeutically effective amount” refers to an amount of a compound or of a pharmaceutical composition useful for treating or ameliorating an identified disease, disorder, or condition, or for exhibiting a detectable therapeutic or inhibitory effect. The exact amounts will depend on the purpose of the treatment and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992);Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations ( 1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).

[0041] “Treat,” “treating,” and “treatment” refer to any indicia of success in the treatment or amelioration of an injury, pathology, disease, disorder, or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology, disease, disorder, or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; and / or improving a patient's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters, including the results of a physical examination, neuropsychiatric exams, and / or a psychiatric evaluation. Treatment may also be preemptive in nature; i.e., it may include prevention of a disease, disorder, or condition, prevention of onset of one or more symptoms of a disease, disorder, or condition, and / or prevention of escalation of a disease, disorder, or condition. Prevention of a disease, disorder, or condition may involve complete protection from disease, and / or prevention of disease progression (e.g., to a later stage of the disease, disorder, or condition). For example, prevention of a disease may not mean complete foreclosure of any effect related to the diseases at any level,12 of 3813506481v1Attorney Docket No. 2013404-0236but instead may mean prevention of the symptoms of a disease, disorder, or condition to a clinically significant or detectable level.2. Compounds

[0042] In certain embodiments, the present disclosure provides the recognition that certain pharmacophores or chemical scaffolds can regulate cellular processes such as cytokine production and expression of transcription factors nuclear factor erythroid 2-related factor (NRF2) and aryl hydrocarbon receptor (AHR).

[0043] NRF2 is a stress-responsive transcription factor encoded by the NFE2L2 gene in humans. Although previously considered to function primarily as an antioxidative transcription factor, NRF2 is now recognized to be involved in the cellular response to multiple stressors including xenobiotics, excessive nutrient / metabolite supply, inflammation, and the accumulation of misfolded proteins. Studies using Nrf2 and Keapl knockout mice have provided key insights into the importance of this pathway in protecting cells from exposure to environmental toxins, inflammatory stresses, neurodegeneration, and carcinogenesis.

[0044] Recent evidence suggests that cross talk may exist between AHR and NRF2 pathways. AHR is a ligand-activated transcription factor that belongs to the basic helix-loop-helix / PER-aryl hydrocarbon receptor nuclear translocator (ARNT)-SIM family. When activated by a ligand, AHR translocates to the nucleus and dimerizes with ARNT, another basic helixloop-helix protein. AHR is activated when bound with ligand, usually a planar polyaromatic chemical. Activated AHR then binds to xenobiotic response elements (XREs) in the promoters of various cytochrome P450s (CYPs), resulting in increased expression of these enzymes.

[0045] Studies utilizing Ahr knockout mice and cell lines revealed that AHR signaling may be involved also in physiological processes, such as growth and differentiation, in a manner that is independent of exogenous ligand. Moreover, it has been reported that the AHR pathway is involved in maintaining a balance between promoting and preventing oxidative stress as well as in preventing toxic redox cycles of catechol estrogens. AHR also regulates gene expression involved in cytoskeletal organization, bioenergetics, and cell proliferation.

[0046] In some embodiments, the present disclosure provides compounds which induce cytokine production. In some embodiments, the present disclosure provides compounds which induce cytokine production. In some embodiments, the present disclosure provides compounds which repress cytokine production. In some embodiments, the present disclosure provides 13 of 3813506481v1Attorney Docket No. 2013404-0236compounds which activate NRF2. In some embodiments, the present disclosure provides compounds which activate AHR. In some embodiments, the present disclosure provides compounds which activate NRF2 but do not activate AHR. In some embodiments, the present disclosure provides compounds which activate AHR but do not activate NRF2. In some embodiments, the present disclosure provides compounds which activate both NRF2 and AHR.

[0047] In some embodiments, the present disclosure provides a compound of formula Ior a pharmaceutically acceptable salt thereof, wherein:X is -O- or -CH2-;R1is Ci-6 aliphatic, -(CH2)xCy1, or -(CH2)yN(R)2;R2is Ci-6 aliphatic or Cy2;Cy1is phenyl or a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Cy2is phenyl, a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;R3and R3are each independently hydrogen or -CH3;R is hydrogen or C1-6 aliphatic;x is 0-3; andy is 2-4.

[0048] As defined generally above, X is -O- or -CH2-. In some embodiments of formula I, X is -O-. In some embodiments of formula I, X is -CH2-.

[0049] As defined generally above, R1is C1-6 aliphatic, -(CH2)xCy1, or -(CH2)yN(R)2. In some embodiments, R1is C1-6 aliphatic. In some such embodiments, R1is C2-s aliphatic. In some embodiments, R1is n-pentyl.

[0050] In some embodiments, R1is -(CH2)yN(R)2.14 of 3813506481v1Attorney Docket No. 2013404-0236

[0051] In some embodiments, R1is -(CH2)xCy1. Accordingly, in some embodiments, the present disclosure provides a compound of formula I-a or formula I-b:or a pharmaceutically acceptable salt thereof.

[0052] As defined generally above, R2is Ci-6 aliphatic or Cy2. In some embodiments of any of formula I, I-a, or I-b, R2is Ci-6 aliphatic. In some such embodiments, R2is C1-3 aliphatic. In some embodiments of any of formula I, I-a, or I-b, R2is n-propyl or isopropyl.

[0053] In some embodiments, R2is Cy2. Accordingly, in some embodiments, the present disclosure provides a compound of formula I-c or formula I-d:or a pharmaceutically acceptable salt thereof.

[0054] In some embodiments of formula I-a or formula I-b, R2is Cy2.

[0055] Accordingly, in some embodiments, the present disclosure provides a compound of formula I-a- / or formula I-b-z:or a pharmaceutically acceptable salt thereof.

[0056] In some embodiments of formula I-c or formula I-d, R1is C1-6 aliphatic.15 of 3813506481v1Attorney Docket No. 2013404-0236

[0057] As defined generally above, Cy1is phenyl or a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments of any of formulae I, I-a, I-b, I-c, or I-d, Cy1is phenyl. In some embodiments of any of formulae I, I-a, I-b, I-c, or I-d, Cy1is a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some such embodiments, Cy1is a 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Cy1is a 6-membered heterocyclic ring having 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Cy1is morpholinyl.

[0058] As defined generally above, Cy2is phenyl, a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments of any of formulae I, I-a, I-b, I-c, or I-d, Cy2is phenyl. In some embodiments of any of formulae I, I-a, I-b, I-c, or I-d, Cy2is a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some such embodiments, Cy2is a 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Cy2is morpholinyl. In some embodiments of any of formulae I, I-a, I-b, I-c, or I-d, Cy2is a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some such embodiments, Cy2is a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some such embodiments, Cy2is a 5-membered heteroaryl ring having 1 heteroatom selected from nitrogen, oxygen, and sulfur. In some embodiments, Cy2is furanyl.

[0059] In some embodiments of any of formulae I-b, I-b-z, or I-d, at least one of Cy1and Cy2is phenyl. In some embodiments of formulae I-a, I-a-z, or I-c, Cy2is not phenyl.

[0060] As defined generally above, R3and R3are each independently hydrogen or -CH3. In some embodiments of any of formulae I, I-b, I-b-z, or I-d, at least one of R3and R3is hydrogen. In some embodiments of any of formulae I, I-b, I-b-z, or I-d, at least one of R3and R3is -CH3. In some embodiments of any of formulae I, I-b, I-b-z, or I-d, each of R3and R3is hydrogen. In some embodiments of any of formulae I, I-b, I-b-z, or I-d, each of R3and R3is -CH3.16 of 3813506481v1Attorney Docket No. 2013404-0236

[0061] As defined generally above, R is hydrogen or Ci-6 aliphatic. In some embodiments of any of formulae I, I-c, or I-d, R is hydrogen. In some embodiments of any of formulae I, I-c, or I-d, R is Ci-6 aliphatic. In some such embodiments, R is C1-4 aliphatic. In some embodiments, R is C1-2 aliphatic.

[0062] As defined generally above, x is 0-3. In some embodiments, x is 0. In some embodiments, x is 1-3. In some embodiments, x is 2-3. In some embodiments, x is 2. In some embodiments, x is 3.

[0063] As defined generally above, y is 2-4. In some embodiments, y is 2. In some embodiments, y is 3. In some embodiments, y is 4.

[0064] In some embodiments, the present disclosure provides a compound of formula I-a-zz or I-a-zzz:or a pharmaceutically acceptable salt thereof.

[0065] In some embodiments of formula I-a-zzz, R2is not phenyl.

[0066] In some embodiments, the present disclosure provides a compound of formula I-a-zv, I-a-v, I-b-zz, or I-b-zzz:17 of 3813506481v1Attorney Docket No. 2013404-0236or a pharmaceutically acceptable salt thereof.

[0067] In some embodiments, the present disclosure provides a compound of formula I-a-vz:or a pharmaceutically acceptable salt thereof.

[0068] In some embodiments, a compound of formula I is selected from:18 of 3813506481v1Attorney Docket No. 2013404-0236or a pharmaceutically acceptable salt thereof.3. Uses, Formulation and AdministrationPharmaceutically Acceptable Compositions

[0069] In some embodiments, the present disclosure provides a composition comprising a compound provided herein, or a pharmaceutically acceptable derivative (e.g., salt) thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of compound in compositions provided herein is such that is effective to modulate a transcription factor, in a biological sample or in a patient. In some embodiments, a transcription factor is AHR or NRF.

[0070] In certain embodiments, a composition provided herein is formulated for administration to a patient in need of such composition. In some embodiments, a composition provided herein is formulated for oral administration to a patient.

[0071] The term “patient”, as used herein, means an animal, preferably a mammal, and most preferably a human.19 of 3813506481v1Attorney Docket No. 2013404-0236

[0072] The term “pharmaceutically acceptable carrier, adjuvant, or vehicle” refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions provided herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

[0073] A “pharmaceutically acceptable derivative” means any non-toxic salt, ester, salt of an ester or other derivative of a compound provided herein that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound provided herein or an active metabolite or residue thereof.

[0074] Compositions of the present disclosure may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the compositions provided herein may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3 -butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer’s solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.

[0075] For this purpose, any bland fixed oil may be employed including synthetic mono-or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or 20 of 3813506481v1Attorney Docket No. 2013404-0236castor oil, especially in their polyoxy ethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.

[0076] Pharmaceutically acceptable compositions provided herein may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and com starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

[0077] Alternatively, pharmaceutically acceptable compositions provided herein may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

[0078] Pharmaceutically acceptable compositions provided herein may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

[0079] Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.

[0080] For topical applications, provided pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of compounds provided herein include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol,21 of3813506481v1Attorney Docket No. 2013404-0236polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

[0081] For ophthalmic use, provided pharmaceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.

[0082] Pharmaceutically acceptable compositions of this disclosure may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.

[0083] Most preferably, pharmaceutically acceptable compositions of this disclosure are formulated for oral administration.

[0084] The amount of compounds of the present disclosure that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration. Preferably, provided compositions should be formulated so that a dosage of between 0.01 - 100 mg / kg body weight / day of the compound can be administered to a patient receiving these compositions.

[0085] It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of a compound of the present disclosure in the composition will also depend upon the particular compound in the composition.22 of 3813506481v1Attorney Docket No. 2013404-0236Uses of Compounds and Pharmaceutically Acceptable Compositions

[0086] Compounds and compositions described herein are generally useful for the modulation of a transcription factor such as, AHR or NRF2.

[0087] Skin is constantly exposed to environmental insults, including toxic chemicals and oxidative stress. These insults often provoke perturbation of epidermal homeostasis and lead to characteristic skin diseases. AHR (aryl hydrocarbon receptor) and NRF2 (nuclear factor erythroid 2-related factor 2) are transcription factors that induce a battery of cytoprotective genes encoding detoxication and antioxidant enzymes in response to environmental insults. In addition to their basic functions as key regulators of xenobiotic and oxidant detoxification, recent investigations revealed that AHR and NRF2 also play critical roles in the maintenance of skin homeostasis. In fact, specific disruption of AHR function in the skin has been found to be associated with the pathogenesis of various skin diseases, most prevalently atopic dermatitis (AD).

[0088] Transcription factor AHR (aryl hydrocarbon receptor) is a ligand-activated transcription factor that belongs to a basic helix-loop-helix / PER-ARNT-SIM (bHLH-PAS) family. AHR is activated by the binding of a large variety of exogenous ligands, which include environmental pollutants such as polycyclic aromatic hydrocarbons (PAHs) and dioxins. In the absence of a ligand, AHR forms a complex in the cytoplasm with at least three factors: Heat shock protein 90 (HSP90), the cochaperone protein p23 and hepatitis B virus X-associated protein 2 (XAP2). Upon binding of certain ligands to AHR, the AHR-HSP90-p23-XAP2 complex is disrupted, leading to the nuclear translocation of AHR.

[0089] In the nucleus, AHR dimerizes with ARNT (AHR nuclear translocator). The AHRARNT heterodimer binds to XRE (xenobiotic response element) in regulatory regions of various AHR-target genes. Prototype AHR-target genes include phase I detoxification enzymes such as cytochrome P450 (CYPs). Two AHR regulatory mechanisms have been reported. One is proteasomal degradation of the AHR protein, while the other is negative feedback regulation of AHR activation by the AHR repressor (AHRR). AHRR is known to be an AHR-target gene, and AHRR inhibits AHR activity by competing with AHR for dimerization with ARNT.

[0090] NRF2 (nuclear factor erythroid 2-related factor 2) is a transcription factor belonging to the cap‘n’collar (CNC) family. NRF2 possesses a basic leucine zipper (bZIP) and a CNC structure. NRF2 induces a battery of cytoprotective genes in response to oxidative and 23 of 3813506481v1Attorney Docket No. 2013404-0236electrophilic stresses. Under physiological conditions, NRF2 is bound by the repressor protein KEAP1 (kelch-like ECH-associated protein 1) in the cytoplasm, which promotes NRF2 degradation by the ubiquitin-proteasome pathway. Upon exposure to oxidative or electrophilic stresses, specific reactive cysteine residues of KEAP1 are modified, which leads to the disruption of the KEAP1-NRF2 interaction. This stabilizes NRF2 so that NRF2 translocates to the nucleus and forms a heterodimer with small MAF (sMAF) protein. The NRF2-sMAF heterodimer complex binds to the CNC-sMAF binding element (CsMBE), which is also known as the antioxidant response element (ARE) or electrophile response element (EpRE), in the regulatory regions of target genes. Closer examination of the NRF2-target genes revealed that a set of genes encoding phase II detoxification enzymes such as glutathione S-transf erase (GSTs), anti oxidative enzymes such as NAD(P)H: quinone oxidoreductase 1 (NQ01), glutamate-cysteine ligase catalytic subunit (GCLC) and phase III transporters such as multidrug-resistance-associated proteins (MRPs) in a member of ATP -binding cassette (ABC) transporters are the target genes of NRF2.

[0091] The primary function of the skin is a surface barrier, which prevents dehydration and protects the body from environmental insults. Therefore, impairment of the skin barrier function facilitates the absorption of environmental toxicants and leads to enhanced water loss. Ligand-activated AHR can act to induce the expression of genes involved in skin barrier formation. Nrf2 is involved in the regulation of epidermal homeostasis, and analyses of several genetically modified mice support this notion. Systemic Keapl -knockout mice in which Nrf2 activity is constitutively activated macroscopically exhibit scaling skin, and histological examinations reveal the presence of severe hyperkeratosis in the skin, esophagus and forestomach. Keapl -knockout mice die before weaning due to obstruction of the esophagus and forestomach caused by hyperkeratosis of the squamous cell epithelium. As epithelial dysfunction can be rescued by concomitant Nrf2 gene deletion, high-level activation of Nr£2 in keratinocytes caused by Keapl deletion must be the reason for epithelial abnormalities.

[0092] Atopic dermatitis (AD) is a chronic recurrent inflammatory skin disease characterized by epidermal barrier dysfunction and immune dysregulation. AD patients account for up to 25% of children and 2-3% of adults. While the pathophysiology of AD appears to be multifactorial with complex interactions between genetic and environmental factors, the recent increase in the prevalence of AD supports the attribution of environmental factors in predisposed 24 of 3813506481v1Attorney Docket No. 2013404-0236individuals. AHR activation improves skin barrier function by accelerating epidermal terminal differentiation. However, although AHR activation acts to repair skin barrier function, but in turn, excessive expression of AHR leads to the development of AD. Without wishing to be bound by any particular theory, it is believed that AHR is a potential therapeutic target, and moderate-level activation of AhR may have therapeutic efficacy for skin barrier recovery. In contrast, AHR inhibitors seem to be important for the treatment of AD.

[0093] In some embodiments, the present disclosure provides a method of modulating a transcription factor, e.g., AHR orNRF2, the method comprising contacting a biological sample or administering to a patient a compound of formula I, or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a method of treating a disease or disorder associated with or modulated by AHR or NRF2, the method comprising administering to a patient a compound of formula I, or a pharmaceutically acceptable salt thereof. In some embodiments, a compound of formula I, or a pharmaceutically acceptable salt thereof, is administered in a therapeutically effective amount.

[0094] In some embodiments, a disease or disorder associated with or modulated by AHR or NRF2 is an inflammatory disease or disorder. In some such embodiments, an inflammatory disease or disorder is an inflammatory skin disorder. In some embodiments, a disease or disorder associated with or modulated by AHR or NRF2 is a cancer. In some embodiments, a disease or disorder associated with or modulated by AHR or NRF2 is diabetes. In some embodiments, a disease or disorder associated with or modulated by AHR or NRF2 is an age-related disorder. In some embodiments, a disease or disorder associated with or modulated by AHR or NRF2 is fibrosis. In some embodiments, a disease or disorder associated with or modulated by AHR or NRF2 is a disorder of the central nervous system. In some embodiments, a disorder of the central nervous system is a neurodegenerative disorder. In some embodiments, a neurodegenerative disorder is a dementia-type disease such as Alzheimer’s disease, frontotemporal dementia, chronic traumatic encephalopathy (CTE), Lewy body dementia, limbic predominant age-related TDP-43 encephalopathy (LATE), a demyelinating disease such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), a Parkinsonismtype disease such as Parkinson’s disease and other forms of parkinsonism, a motor neuron disease such as amyotrophic lateral sclerosis (ALS) and progressive supranuclear palsy (PSP), or a prion disease such as Creutzfeldt-Iakob disease, or Huntington’s disease.25 of 3813506481v1Attorney Docket No. 2013404-0236

[0095] In some embodiments, the present disclosure provides a method of regulating one or more of cell quiescence, cell differentiation, or cell migration, the method comprising contacting a biological sample or administering to a patient a compound of formula I, or a pharmaceutically acceptable salt thereof.

[0096] In some embodiments, the present disclosure provides a method of regulating the expression levels of one or more cytokines, the method comprising contacting a biological sample or administering to a patient a compound of formula I, or a pharmaceutically acceptable salt thereof. In some embodiments, a cytokine that is capable of being regulated by a compound of formula I, or a pharmaceutically acceptable salt thereof, is selected from eotaxin, IL-7, MIG, IL-la, IL-2, G-CSF, IL-16, 6Ckine / Exodus2, GM-CSF, IL-ip, IL-15, IL-3, IL-4, IL-6, IL-11, IL-17, LIF, LIX, M-CSF, MDC, IL-13, MCP-1, MCP-5, MIP-la, MIP-1, IFNP-1, TNFa, and VEGF. In some embodiments, a provided method comprises reducing the level of at least one cytokine selected from G-CSF, IL-16, 6Ckine / Exodus2, GM-CSF, IL-ip, IL-3, IL-4, IL-6, IL-11, IL- 17, LIF, LIX, M-CSF, MCP-1, MCP-5, MIP-la, MIP-ip, TFN -1, TNFa, and VEGF as compared to a baseline level. In some embodiments, a provided method comprises reducing the level of two or more cytokines selected from G-CSF, IL-16, 6Ckine / Exodus2, GM-CSF, IL-ip, IL-3, IL-4, IL-6, IL-11, IL-17, LIF, LIX, M-CSF, MCP-1, MCP-5, MIP-la, MIP-10, IFNP-1, TNFa, and VEGF as compared to a baseline level.

[0097] In some embodiments, a provided method comprises increasing or inducing the level of at least one cytokine selected from eotaxin, IL-7, MIG, IL-la, IL-2, IL- 15, MDC, and IL-13 as compared to a baseline level. In some embodiments, a provided method comprises increasing or inducing the level of two or more cytokines selected from eotaxin, IL-7, MIG, IL-la, IL-2, IL- 15, MDC, and IL- 13 as compared to a baseline level.EXAMPLES

[0098] Example 1. Inflammation of the mouse ear tissue was induced by exposing the mouse ear to 0.8% oxazolone on day 0, 0.4% on days 7, 9, 11 and 14. Beginning on day 11 after oxazolone exposure, mice were treated topically with Vehicle (Versa Penn gel), 0.1% compound 1-4, or 0.05% Clobetasol (positive control). Mice ears were measured via caliper on days 0, 4, 7, 9, 11, 13, 14, 15, 16, 17, and 18 (p values obtained from ANOVA with a Holm-Sidak correction;26 of 3813506481v1Attorney Docket No. 2013404-0236**** = p<0.0001 ). As shown in FIG. 1, mice treated with compound T-4 showed statistically significant reduction in ear thickness (mm) as compared to vehicle.

[0099] On Day 18 of the study, ear tissue was harvested and the tissue was processed for histology by hematoxylin and eosin staining and imaged. Imaging was performed on Zeiss Axio microscope and analyzed in ImageJ software (p values obtained by ANOVA with Holm-Sidak correction; *=p<0.05, ****=p<0.0001). As shown in FIG. 2, mice treated with compound 1-4 showed statistically significant reduction in epithelial thickness (pm) as compared to vehicle.

[0100] Ear tissue was homogenized and the lysate was processed for analysis of cytokines for mice treated with vehicle, compound 1-4, or Clobetasol (p values obtained by ANOVA with Tukey correction; *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001). As shown in FIG. 3A, compound 1-4 induced levels of cytokines eotaxin (p<0.0001), IL-7 (p<0.05), MIG (p<0.01), IL-la (p<0.0001), and IL-2 (p<0.0001) as compared to vehicle. As shown in FIG. 3A, compound 1-4 reduced levels of cytokines G-CSF (p<0.01), IL-16 (p<0.001), 6Ckine / Exodus2 (p<0.01), GM-CSF (p<0.0001), and IL-ip (p<0.0001) as compared to vehicle.

[0101] As shown in FIG. 3B, compound 1-4 induced levels of cytokine IL-15 (p<0.001) as compared to vehicle. As shown in FIG. 3B, compound 1-4 reduced levels of cytokines IL-3 (p<0.0001), IL-4 (p<0.0001), IL-6 (pO. OOl), IL-11 (pO. OOl), IL-17 (p<0.0001), LIF (p<0.0001), LIX (p<0.01), and M-CSF (p<0.0001) as compared to vehicle.

[0102] As shown in FIG. 3C, compound 1-4 induced levels of cytokines MDC (p<0.001) and IL-13 (p<0.01) as compared to vehicle. As shown in FIG. 3C, compound 1-4 reduced levels of cytokines MCP-1 (p<0.05), MCP-5 (p<0.05), MIP-la (p<0.0001), MIP-ip (p<0.0001), IFNP-1 (p<0.0001), TNFa (p<0.0001), and VEGF (p<0.0001) as compared to vehicle.

[0103] Example 2. Mice were injected with vehicle or 10 mg / kg compound 1-4 from days 0 to 2. On day 2 the mice were euthanized, and brain tissue was harvested, homogenate was generated and analyzed by LCMS for the presence of the compound (p values obtained with a Mann-Whitney statistical test; ****=p<0.0001). As shown in FIG. 4, compound 1-4 is present in brain tissue of mice treated with the compound i.p. (p<0.0001) as compared to vehicle.

[0104] Example 3. Mice were gavaged once daily with vehicle or 250 mg / kg compound 1-5 from days 0 to 7. On day 7 the mice were euthanized, and brain tissue was harvested, homogenized and analyzed by LCMS for the presence of the compound mice (p values obtained27 of 3813506481v1Attorney Docket No. 2013404-0236with a Mann-Whitney statistical test; *=p<0.05). As shown in FIG. 5, compound T-4 is present in brain tissue of mice treated with the compound p.o. (p<0.05) as compared to vehicle.28 of 3813506481v1

Claims

1. Attorney Docket No. 2013404-0236CLAIMS1. A compound of formula Ior a pharmaceutically acceptable salt thereof, wherein:X is -O- or -CH2-;R1is C1-6 aliphatic,R2is C1-6 aliphaticCy1is phenyl or a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;Cy2is phenyl, a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;R3and R3are each independently hydrogen or -CH3;R is hydrogen or C1-6 aliphatic;x is 0-3; andy is 2-4.

2. The compound according to claim 1, wherein X is -O-.

3. The compound according to claim 1, wherein X is -CH2-.

4. The compound according to claim 1, wherein the compound is of formula I-a or formula Lb:29 of 3813506481v1Attorney Docket No. 2013404-0236or a pharmaceutically acceptable salt thereof.

5. The compound according to any one of claims 1-4, wherein R2is n-propyl or isopropyl.

6. The compound according to any one of claims 1-4, wherein R2is Cy2.

7. The compound according to claim 1, wherein the compound is of formula 1-c or formula I-d:or a pharmaceutically acceptable salt thereof.

8. The compound according to any one of claims 1-3 or 5-7, wherein R1is Ci-6 aliphatic.

9. The compound according to any one of claims 1-3 or 5-7, wherein R1is -(CH2)yN(R)2.

10. The compound according to claim 1, wherein the compound is of formula I-a- / or formula I-b-z:30 of 3813506481v1Attorney Docket No. 2013404-0236or a pharmaceutically acceptable salt thereof.

11. The compound according to claim 1, wherein the compound is of formula I-a-zv, I-a-v, I-b-zz, or I-b-iiiI-a-r I-b-z’zz or a pharmaceutically acceptable salt thereof.

12. The compound according to claim 1, wherein the compound is of formula I-a-iv:I-n-vior a pharmaceutically acceptable salt thereof.31 of3813506481v1Attorney Docket No. 2013404-023613. The compound according to any one of claims 1-7 or 10-12, wherein Cy1is phenyl.

14. The compound according to any one of claims 1-7 or 10-12, wherein Cy1is a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

15. The compound according to any one of claims 1-7 or 10-12, wherein Cy1is a 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

16. The compound according to any one of claims 1-7 or 10-12, wherein Cy1is a 6-membered heterocyclic ring having 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

17. The compound according to any one of claims 1-7 or 10-12, wherein Cy1is morpholinyl.

18. The compound according to any one of claims 1-4 or 6-11, wherein Cy2is phenyl.

19. The compound according to any one of claims 1-4 or 6-11, wherein Cy2is a 5- to 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

20. The compound according to any one of claims 1-4 or 6-11, wherein Cy2is a 6-membered heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

21. The compound according to any one of claims 1-4 or 6-11, wherein Cy2is morpholinyl.

22. The compound according to any one of claims 1-4 or 6-11, wherein Cy2is a 5- to 6-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.32 of 3813506481v1Attorney Docket No. 2013404-023623. The compound according to any one of claims 1-4 or 6-11, wherein Cy2is a 5-membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

24. The compound according to any one of claims 1-4 or 6-11, wherein Cy2is a 5-membered heteroaryl ring having 1 heteroatom selected from nitrogen, oxygen, and sulfur.

25. The compound according to any one of claims 1-4 or 6-11, wherein Cy2is furanyl.

26. The compound according to any one of claims 1-25, wherein at least one of Cy1and Cy2is phenyl.

27. The compound according to any one of claims 1-25, wherein Cy2is not phenyl.

28. The compound according to any one of claims 1-10 or 13-27, wherein at least one of R3and R3is hydrogen.

29. The compound according to claim 28, wherein at least one of R3and R3is -CH3.

30. The compound according to claim 28, wherein each of R3and R3is hydrogen.

31. The compound according to claim 28, wherein each of R3and R3is -CH3.

32. The compound according to any one of claims 1-31, wherein R is hydrogen or C1-6 aliphatic.

33. The compound according to claim 28, wherein R is hydrogen.

34. The compound according to claim 28, wherein R is C1-6 aliphatic.

35. The compound according to claim 28, wherein R is C1-2 aliphatic.33 of 3813506481v1Attorney Docket No. 2013404-023636. The compound according to any one of claims 1-7, 10, or 12-35, wherein x is 0.

37. The compound according to any one of claims 1-7, 10, or 12-35, wherein x is 2-3.

38. The compound according to any one of claims 1-3, 5-7, 9, or 12-35, wherein y is 2.

39. The compound according to claim 1, wherein the compound is selected from34 of 3813506481v1Attorney Docket No. 2013404-0236or a pharmaceutically acceptable salt thereof.

40. A pharmaceutical composition comprising a compound according to any one of claims 1-39, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

41. The compound according to any one of claims 1-39, or a pharmaceutically acceptable salt thereof, for use in medicine.

42. A method of modulating a transcription factor, e.g., AHR or NRF2, the method comprising contacting a biological sample or administering to a patient a compound according to any one of claims 1-39, or a pharmaceutically acceptable salt thereof.35 of 3813506481v1Attorney Docket No. 2013404-023643. A method of treating a disease or disorder associated with or modulated by AHR or NRF2, the method comprising administering to a patient a compound according to any one of claims 1-39, or a pharmaceutically acceptable salt thereof.

44. The method according to claim 43, wherein the disease or disorder associated with or modulated by AHR or NRF2 is selected from an inflammatory disease or disorder, a cancer, a metabolic disorder such as diabetes, an age-related disorder, fibrosis, a disorder of the central nervous system, or a neurodegenerative disorder.

45. The method according to claim 44, wherein the inflammatory disease or disorder is an inflammatory skin disorder.

46. The method according to claim 44, wherein the neurodegenerative disorder is a dementiatype disease such as Alzheimer’s disease, frontotemporal dementia, chronic traumatic encephalopathy (CTE), Lewy body dementia, limbic predominant age-related TDP-43 encephalopathy (LATE), a demyelinating disease such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), a Parkinsonism-type disease such as Parkinson’s disease and other forms of parkinsonism, a motor neuron disease such as amyotrophic lateral sclerosis (ALS) and progressive supranuclear palsy (PSP), or a prion disease such as Creutzfeldt-Jakob disease, or Huntington’s disease.

47. A method of regulating one or more of cell quiescence, cell differentiation, or cell migration, the method comprising contacting a biological sample or administering to a patient a compound according to any one of claims 1-39, or a pharmaceutically acceptable salt thereof.

48. A method of regulating the expression levels of one or more cytokines, the method comprising contacting a biological sample or administering to a patient a compound according to any one of claims 1-39, or a pharmaceutically acceptable salt thereof.

49. The method according to claim 48, wherein the cytokine is selected from eotaxin, IL-7, MIG, IL-la, IL-2, G-CSF, IL-16, 6Ckine / Exodus2, GM-CSF, IL-1, IL-15, IL-3, IL-4, IL-6, IL- 36 of 3813506481v1Attorney Docket No. 2013404-023611, IL-17, LIF, LIX, M-CSF, MDC, IL-13, MCP-1, MCP-5, MIP-la, MIP-10, IFNp-1, TNFa, and VEGF.

50. The method according to claim 49, wherein the method comprises reducing the level of at least one cytokine selected from G-CSF, IL-16, 6Ckine / Exodus2, GM-CSF, IL-10, IL-3, IL-4, IL-6, IL-11, IL-17, LIF, LIX, M-CSF, MCP-1, MCP-5, MIP-la, MIP-10, IFN0-1, TNFa, and VEGF as compared to a baseline level.

51. The method according to claim 49, wherein the method comprises increasing or inducing the level of at least one cytokine selected from eotaxin, IL-7, MIG, IL-la, IL-2, IL-15, MDC, and IL- 13 as compared to a baseline level.

52. Use of a compound according to any one of claims 1-39, in the preparation of a medicament for use in medicine.37 of 3813506481v1